Intervention Strategies and Agents Mediating the Prevention of Xenorejection
- 1 November 2005
- journal article
- review article
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 1056 (1) , 123-143
Abstract
Xenotransplantation, the transplantation of cells, tissues, and/or organs across species, has proven to be an enormous challenge, resulting in only limited achievements over the last century. Unlike allotransplantation, the immunologic barriers involved in xenotransplant rejection are aggressive and usually occur within minutes in a hyperacute fashion. The use of organs from phylogenetically related concordant species may not be practical. Discordant xenotransplantation is characterized by hyperacute graft rejection, and to use nonprimate discordant organs for human benefit will require manipulation of the taxonomic differences. The hyperacute rejection process is primarily due to the attachment of preformed xenoreactive antibodies to the donor vascular endothelium, which results in hyperactivation of the complement system beyond the control of the natural complement regulatory proteins. Understanding the complex and diverse immune components involved in hyperacute, acute, and accelerated rejections has resulted in the development of different hematologic and molecular strategies. Plasmapheresis has been used to remove xenoantibodies, and xenoperfusion techniques are used to create a suitable and familiar environment for the xenograft. Various molecular approaches, such as the development of transgenic animals expressing human complement regulatory proteins such as CD59 or decay accelerating factor (DAF), to downregulate complement activation or the production of pigs lacking the xenoreactive antigen by knockout of the Galα‐1,3‐galactosyl transferase gene have also been attempted. A combination of these techniques together with the administration of soluble complement inhibitors such as the vaccinia virus complement control protein (VCP) may well contribute to prolong graft survival. However, various issues including the possible emergence of new viral infections have confounded the topic of xenotransplantation. Here the different modulatory approaches and agents mediating interventions in xenorejection are discussed.Keywords
This publication has 86 references indexed in Scilit:
- Vaccinia virus complement control protein inhibits hyperacute xenorejection in a guinea pig-to-rat heterotopic cervical cardiac xenograft model by blocking both xenoantibody binding and complement pathway activationTransplant Immunology, 2003
- 25 days of baboons after orthotopic xenotransplantation of hDAF transgenic PIG hearts using a moderate immunosuppressionThe Journal of Heart and Lung Transplantation, 2003
- Xenotransplantation—how far have we come?Transplant Immunology, 2002
- RETRACTED: Crystal Structure of a Complement Control Protein that Regulates Both Pathways of Complement Activation and Binds Heparan Sulfate ProteoglycansCell, 2001
- Delayed xenograft rejectionImmunology Today, 1996
- Xenotransplantation: Risks, Clinical Potential, and Future ProspectsEmerging Infectious Diseases, 1996
- CONTRIBUTION OF ANTI-GAL TO PRIMATE AND HUMAN IgG BINDING TO PORCINE ENDOTHELIAL CELLSTransplantation, 1995
- REMOVAL OF NATURAL HUMAN XENOANTIBODIES TO PIG VASCULAR ENDOTHELIUM BY PERFUSION OF BLOOD THROUGH PIG KIDNEYS AND LIVERSTransplantation, 1993
- Transplantation of discordant xenografts: a review of progressImmunology Today, 1990
- THE MECHANISM OF DISCORDANT XENOGRAFT REJECTIONTransplantation, 1988